Biotinylated selenocyanates: Potent and selective cytostatic agents

Area of Science:

• Medicinal Chemistry
• Oncology
• Drug Discovery

Background:

• Current cytotoxic chemotherapy agents lack selectivity, leading to severe side effects.
• Selenium-containing compounds show promise as prodrugs releasing reactive species in tumor cells.
• Targeting cancer cells selectively is crucial for improving therapeutic outcomes.

Purpose of the Study:

• To develop novel antiproliferative agents with enhanced affinity for tumor cells.
• To synthesize and evaluate biotinylated selenium compounds as targeted cancer therapeutics.
• To investigate the mechanism of action and overcome multidrug resistance.

Main Methods:

• Synthesis of novel selenocyanate derivatives conjugated with biotin.
• Evaluation of antiproliferative activity (GI50 values) against various cancer cell lines and human fibroblasts.
• Mechanistic studies including Annexin-V assay, mitochondrial membrane potential analysis, and label-free cell-living imaging.
• Assessment of multidrug resistance and efficacy of P-gp inhibitor co-administration.

Main Results:

• The optimized biotinylated selenocyanate derivative exhibited potent antiproliferative activity in the low nanomolar range (GI50) against tested cancer cells.
• The compound demonstrated outstanding selectivity, with GI50 > 100 µM against human fibroblasts.
• Mechanistic studies confirmed induction of apoptosis and prevention of tumor cell division.
• Co-administration with tariquidar restored antiproliferative activity in multidrug-resistant cell lines, overcoming P-gp-mediated efflux.

Conclusions:

• Biotinylated selenocyanates represent a promising class of targeted anticancer agents with high potency and selectivity.
• The developed compound effectively induces apoptosis and cytostatic effects in cancer cells.
• This strategy can overcome P-gp-mediated multidrug resistance, offering potential for improved cancer therapy.